Related references
Note: Only part of the references are listed.Association of Area Sociodemographic Characteristics and Capacity for Treatment With Disparities in Colorectal Cancer Care and Mortality
Jennifer S. Haas et al.
CANCER (2011)
Patient and healthcare professional factors influencing end-of-life decision-making during critical illness: A systematic review
David W. Frost et al.
CRITICAL CARE MEDICINE (2011)
The Role of Organizational Affiliations and Research Networks in the Diffusion of Breast Cancer Treatment Innovation
William R. Carpenter et al.
MEDICAL CARE (2011)
Treatment Effects in the Presence of Unmeasured Confounding: Dealing With Observations in the Tails of the Propensity Score Distribution-A Simulation Study
Til Stuermer et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2010)
Translating Research Into Evidence-Based Practice The National Cancer Institute Community Clinical Oncology Program
Lori M. Minasian et al.
CANCER (2010)
Racial Differences in Advanced Colorectal Cancer Outcomes and Pharmacogenetics: A Subgroup Analysis of a Large Randomized Clinical Trial
Hanna K. Sanoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial
Thierry Andre et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Residual treatment disparities after oncology referral for rectal cancer
Arden M. Morris et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Strengthening the reporting of observational studies in epidemiology (STROBE): Explanation and elaboration
Jan P. Vandenbroucke et al.
PLOS MEDICINE (2007)
A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients
Carrie N. Klabunde et al.
ANNALS OF EPIDEMIOLOGY (2007)
Racial disparities and socioeconomic status in association with survival in a large population-based cohort of elderly patients with colon cancer
Xianglin L. Du et al.
CANCER (2007)
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: Results from NSABP C-07
J. Philip Kuebler et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Test for additive interaction in proportional hazards models
Rongling Li et al.
ANNALS OF EPIDEMIOLOGY (2007)
Racial differences in trust in health care providers
CH Halbert et al.
ARCHIVES OF INTERNAL MEDICINE (2006)
Emerging and widening colorectal carcinoma disparities between blacks and whites in the United States (1975-2002)
K Irby et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2006)
Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: Final report of Intergroup 0089
DG Haller et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Current research findings on end-of-life decision making among racially or ethnically diverse groups
J Kwak et al.
GERONTOLOGIST (2005)
Explaining black-white differences in receipt of recommended colon cancer treatment
LM Baldwin et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Racial differences in screening for prostate cancer in the elderly
T Gilligan et al.
ARCHIVES OF INTERNAL MEDICINE (2004)
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer
T Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Race and trust in the health care system
LE Boulware et al.
PUBLIC HEALTH REPORTS (2003)
Racial differences in the outcome of patients with colorectal carcinoma
R Govindarajan et al.
CANCER (2003)
Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer
AL Potosky et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Effects of health insurance and race on colorectal cancer treatments and outcomes
RG Roetzheim et al.
AMERICAN JOURNAL OF PUBLIC HEALTH (2000)
Share Paper
